TY - JOUR
T1 - Fueling the revolution
T2 - Targeting metabolism to enhance immunotherapy
AU - Leone, Robert D.
AU - Powell, Jonathan D.
N1 - Publisher Copyright:
© 2021 American Association for Cancer Research.
PY - 2021/3/1
Y1 - 2021/3/1
N2 - The success of immune-checkpoint blockade and chimeric antigen receptor (CAR) T cell therapies has established the remarkable capacity of the immune system to fight cancer. Over the past several years, it has become clear that immune cell responses to cancer are critically dependent upon metabolic programs that are specific to both immune cell type and function. Metabolic features of cancer cells and the tumor microenvironment impose constraints on immune cell metabolism that can favor immunosuppressive phenotypes and block antitumor responses. Advances in both preclinical and clinical studies have demonstrated that metabolic interventions can dramatically enhance the efficacy of immune-based therapies for cancer. As such, understanding the metabolic requirements of immune cells in the tumor microenvironment, as well as the limitations imposed therein, can have significant benefits for informing both current practice and future research in cancer immunotherapy.
AB - The success of immune-checkpoint blockade and chimeric antigen receptor (CAR) T cell therapies has established the remarkable capacity of the immune system to fight cancer. Over the past several years, it has become clear that immune cell responses to cancer are critically dependent upon metabolic programs that are specific to both immune cell type and function. Metabolic features of cancer cells and the tumor microenvironment impose constraints on immune cell metabolism that can favor immunosuppressive phenotypes and block antitumor responses. Advances in both preclinical and clinical studies have demonstrated that metabolic interventions can dramatically enhance the efficacy of immune-based therapies for cancer. As such, understanding the metabolic requirements of immune cells in the tumor microenvironment, as well as the limitations imposed therein, can have significant benefits for informing both current practice and future research in cancer immunotherapy.
UR - http://www.scopus.com/inward/record.url?scp=85102167529&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85102167529&partnerID=8YFLogxK
U2 - 10.1158/2326-6066.CIR-20-0791
DO - 10.1158/2326-6066.CIR-20-0791
M3 - Article
C2 - 33648947
AN - SCOPUS:85102167529
SN - 2326-6066
VL - 9
SP - 255
EP - 260
JO - Cancer Immunology Research
JF - Cancer Immunology Research
IS - 3
ER -